Skip Navigation



Carcinogenesis Advance Access published online on September 4, 2006

Carcinogenesis, doi:10.1093/carcin/bgl162
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
28/2/404    most recent
bgl162v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Dell'Eva, R.
Right arrow Articles by Ferrari, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dell'Eva, R.
Right arrow Articles by Ferrari, N.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org
Received February 1, 2006
Revised July 25, 2006
Accepted August 13, 2006

CANCER PREVENTION

The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-{kappa}B pathway

Raffaella Dell'Eva 1, Claudia Ambrosini 1, Simona Minghelli 2, Douglas M. Noonan 3, Adriana Albini 1 *, and Nicoletta Ferrari 1

1 Molecular Oncology Laboratory, National Institute for Cancer Research, Genova 16132, Italy
2 Centro di Biotecnologie Avanzate, Genova 16132, Italy
3 Dept of Clinical and Biological Sciences, University of Insubria, Varese 21100, Italy

* To whom correspondence should be addressed.
Adriana Albini, E-mail: adriana.albini{at}istge.it


   Abstract

Several natural compounds, especially plant products and dietary constituents, are able to exhibit "angiopreventive" (anti-angiogenic chemoprevention) activities both in vitro and in vivo. Deguelin is a rotenoid of the flavonoid family with chemopreventive activities able to decrease tumor incidence in animal models for lung, colon, mammary and skin carcinogenesis through Akt inhibition. Here we show that deguelin belongs to the "angiopreventive" molecules and provide evidence for molecular events associated with its anti-angiogenic properties. The data show that deguelin inhibits HUVE cells growth by inducing cell-cycle arrest in the G0/G1 phase and in the absence of apoptosis. Growth arrest is associated with induction of p21 and p53 and decreased survivin levels. Deguelin also interferes with several points in the angiogenic process, including inhibition of endothelial cell migration, invasion, and metalloprotease production, and potently inhibited in vivo angiogenesis and vascular tumor growth. In addition to Akt, the NF-{kappa}B kinase pathway, which plays a critical role in the regulation of inflammation, vascular homeostasis and angiogenesis, was also repressed by deguelin even in the presence of inflammatory stimuli such as TNF{alpha}. These findings reveal a new therapeutic potential for deguelin in angioprevention and anti-angiogenic therapy.

Keywords: Chemoprevention; Angiogenesis; Angioprevention; p21; p53; Survivin.
Note: R. Dell'Eva and C. Ambrosini contributed equally to this study.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
J. A. Crowell, V. E. Steele, and J. R. Fay
Targeting the AKT protein kinase for cancer chemoprevention
Mol. Cancer Ther., August 1, 2007; 6(8): 2139 - 2148.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Albini, D. M. Noonan, and N. Ferrari
Molecular Pathways for Cancer Angioprevention
Clin. Cancer Res., August 1, 2007; 13(15): 4320 - 4325.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.